Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan

LONDON - While insulin syringes are the oldest delivery method available, they are
currently experiencing a decline in use in Europe. Several factors have
contributed to this trend, the most important being the high acceptance and
popularity of insulin pens.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (www.medicaldevices.frost.com),
European Insulin Delivery Devices Market, finds that the market earned
revenues of $1,112.8 million in 2007 and estimates this to reach $1,895.0
million in 2014.

If you are interested in a virtual brochure, which provides
manufacturers, end users, and other industry participants with an overview of
the European insulin delivery devices market, then send an e-mail to Katja
Feick, Corporate Communications, at katja.feick@frost.com, with your full
name, company name, title, telephone number, company e-mail address, company
website, city, state and country. Upon receipt of the above information, an
overview will be sent to you by e-mail.

“The synergies created between pharmaceutical and medical device
companies will be a key driver of the insulin pens market in Europe,” notes
Frost & Sullivan Research Analyst Kieu Vuong. “Another significant factor
spurring growth is that insulin pens are more compatible with the fast paced
modern environment.”

The vast majority of insulin pens are given to patients free when they
purchase insulin. This means that suppliers of insulin have a huge impact on
the popularity and awareness of related devices. Insulin delivery device
manufacturers need to work together with pharmaceutical companies to
successfully distribute and promote their products.

The convenience of using insulin pens corresponds well to the needs of
today’s insulin users. There is a pressing need for a device with high levels
of flexibility that requires little commitment in terms of time and effort.

In order to deliver insulin to the subcutaneous tissue, a needle
injection is the most straightforward method. Needle phobia is however a
significant deterrent for patients.

“Needle phobia has always represented the biggest restraint to the growth
of the insulin syringes market,” explains Vuong. “Needle phobia is not only
an issue among new users and children but also among adult insulin users.”

Perhaps the most effective method to achieve adequate dissemination of
insulin for diabetic patients is through promoting the cooperation of insulin
suppliers (pharmaceutical companies) and insulin delivery device
manufacturers. Currently, only a few big multinational firms manufacture
their own devices.

“Accordingly, one of the biggest and most important challenges for
manufacturers of emerging insulin delivery devices is to build a close
business relationship with pharmaceutical companies,” advises Vuong. “Insulin
pens are a good example of this kind of cooperation.”

Through cooperative agreements and projects, both companies can benefit
from mutual synergies and save on additional capital investments and
operation costs, even while extending their product portfolio.

European Insulin Delivery Devices Market is part of the Medical Devices
Growth Partnership Service programme, which also includes research in the
following markets: European Bone Growth and Spinal Fusion Stimulators
Markets, European Patient Temperature Management Market, European Device
Disinfection and Sterilisation Equipment Market and European Markets for
Haemostats and Tissue Sealants. All research services included in
subscriptions provide detailed market opportunities and industry trends that
have been evaluated following extensive interviews with market participants.
Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate
Growth - GIL Global - into several major cities around the world including
London. For the first time ever in Europe, Frost & Sullivan will be hosting
the Growth, Innovation and Leadership Congress ‘GIL 2009: Europe’ on 19-20
May, at the Sofitel St James in London. GIL Global is the industry’s only
event designed to support senior executives in their efforts to achieve
sustainable, top-line growth. To register, obtain a programme agenda, explore
sponsorship opportunities, or attend as a member of the media for GIL 2009:
Europe, please contact Katja Feick, Corporate Communications Europe, at
katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior
growth consultants are also being scheduled. For more information you can
also visit www.frost.com/gilglobal

Frost & Sullivan, the Growth Partnership Company, partners with clients
to accelerate their growth. The company’s TEAM Research, Growth Consulting
and Growth Team Membership(TM) empower clients to create a growth-focused
culture that generates, evaluates and implements effective growth strategies.
Frost & Sullivan employs over 45 years of experience in partnering with
Global 1000 companies, emerging businesses and the investment community from
more than 30 offices on six continents. For more information about Frost &
Sullivan’s Growth Partnership Services, visit www.frost.com.

European Insulin Delivery Devices Market
M2CD

Contact:
Katja Feick
Corporate Communications - Europe
P: +49-(0)-69-77033-43
E: katja.feick@frost.com
www.frost.com/

Source: Frost & Sullivan

Katja Feick, Corporate Communications - Europe, +49-(0)-69-77033-43, katja.feick at frost.com; Photo: https://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO